We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cassava Sciences, Inc. (SAVA) Gains But Lags Market: What You Should Know
Read MoreHide Full Article
Cassava Sciences, Inc. (SAVA - Free Report) closed at $47.12 in the latest trading session, marking a +0.17% move from the prior day. This change lagged the S&P 500's 0.84% gain on the day. At the same time, the Dow added 1.06%, and the tech-heavy Nasdaq gained 0.1%.
Prior to today's trading, shares of the company had lost 2.77% over the past month. This has was narrower than the Medical sector's loss of 2.97% and the S&P 500's loss of 4.03% in that time.
Cassava Sciences, Inc. will be looking to display strength as it nears its next earnings release. In that report, analysts expect Cassava Sciences, Inc. to post earnings of -$0.41 per share. This would mark a year-over-year decline of 355.56%.
Investors might also notice recent changes to analyst estimates for Cassava Sciences, Inc.Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 72.5% lower. Cassava Sciences, Inc. is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 149, which puts it in the bottom 42% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Cassava Sciences, Inc. (SAVA) Gains But Lags Market: What You Should Know
Cassava Sciences, Inc. (SAVA - Free Report) closed at $47.12 in the latest trading session, marking a +0.17% move from the prior day. This change lagged the S&P 500's 0.84% gain on the day. At the same time, the Dow added 1.06%, and the tech-heavy Nasdaq gained 0.1%.
Prior to today's trading, shares of the company had lost 2.77% over the past month. This has was narrower than the Medical sector's loss of 2.97% and the S&P 500's loss of 4.03% in that time.
Cassava Sciences, Inc. will be looking to display strength as it nears its next earnings release. In that report, analysts expect Cassava Sciences, Inc. to post earnings of -$0.41 per share. This would mark a year-over-year decline of 355.56%.
Investors might also notice recent changes to analyst estimates for Cassava Sciences, Inc.Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 72.5% lower. Cassava Sciences, Inc. is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 149, which puts it in the bottom 42% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.